688246.SH
嘉和美康
SSE · Healthcare · Medical - Distribution · CN
CNY 17.06
−2.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 387.7M | 404.1M | 591.9M | 695.2M | 716.9M |
| Cost of Revenue | 337.9M | 339.0M | 382.5M | 343.7M | 354.6M |
| Gross Profit | 49.8M | 65.1M | 209.4M | 351.5M | 362.3M |
| Operating Expenses | |||||
| R&D Expense | 115.9M | 129.6M | 144.5M | 144.9M | 158.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 77.1M | 84.2M | 90.4M | 83.1M | 82.1M |
| Selling & Marketing Expense | 78.1M | 82.3M | 86.2M | 105.2M | 97.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 283.5M | 308.9M | 332.3M | 332.7M | 333.7M |
| Cost and Expenses | 621.4M | 647.9M | 714.8M | 676.4M | 688.3M |
| Operating Income (EBIT) | (277.3M) | (294.6M) | (228.9M) | (4.7M) | 23.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (277.6M) | (294.9M) | (229.9M) | (4.7M) | 23.3M |
| Income Tax Expense | (11.9M) | (23.2M) | 68.3M | (14.7M) | (14.0M) |
| Bottom Line | |||||
| Net Income | (247.4M) | (250.5M) | (256.1M) | 32.3M | 64.6M |
| Earnings from Cont. Ops | (265.7M) | (271.7M) | (298.2M) | 10.1M | 37.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (247.4M) | (250.5M) | (256.1M) | 32.3M | 64.6M |
| Per Share | |||||
| Basic EPS | (CN¥1.80) | (CN¥1.82) | (CN¥0.31) | CN¥0.23 | CN¥0.47 |
| Diluted EPS | (CN¥1.80) | (CN¥1.82) | (CN¥0.31) | CN¥0.23 | CN¥0.47 |
| Revenue Per Share | CN¥2.71 | CN¥2.94 | — | CN¥4.95 | CN¥5.22 |
| Shares | |||||
| Basic Shares Outstanding | 143.2M | 137.6M | — | 140.4M | 137.4M |
| Diluted Shares Outstanding | 143.2M | 137.6M | — | 140.4M | 137.4M |
| Profitability Metrics | |||||
| EBITDA | — | (251.6M) | (218.9M) | 4.4M | 31.8M |
| D&A | — | 42.9M | 10.1M | 9.1M | 8.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026